Clinical trials: Melanoma Stage IV
Melanoma, Malignant Melanoma
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
The purpose of this research study is to see if the study drug, CT-011, is safe to give and if it helps people with melanoma that has spread to other areas of their body. CT-011 is a monoclonal antibody.
- Trial name
- NCT01435369
- Testing
- CT-011
- Where
- 18 sites in United States, Israel
- Volunteers
- 103 people
- Sponsor
- Medivation, Inc.
Metastatic Melanoma
IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
This is a phase Ib, open label clinical study to evaluate the safety, tolerability, PK and antitumor activities of IN10018 as monotherapy and in combination with cobimetinib in subjects with metastatic uveal melanoma and…
- Trial name
- NCT04109456
- Testing
- IN10018, Cobimetinib, Atezolizumab
- Where
- 8 sites in United States, Australia
- Volunteers
- 51 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Melanoma, Metastatic Melanoma
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
This research study is studying the drugs called NeoVax (a new type of personalized neoantigen vaccine) in combination with CDX-301 and Nivolumab or Pembrolizumab as a possible treatment for melanoma.
- Trial name
- NCT04930783
- Testing
- CDX-301, NEOVAX, Nivolumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Dana-Farber Cancer Institute
Melanoma
Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-145 (JSC BIOCAD, Russia) Monotherapy in Patients with Unresectable/Metastatic Melanoma.
- Trial name
- NCT03472027
- Testing
- BCD-145
- Where
- 4 sites in Russia
- Volunteers
- 15 people
- Sponsor
- Biocad
Recurrent Melanoma, Stage III Melanoma
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
RATIONALE: White blood cells that have been treated in a laboratory may be able to kill tumor cells in patients with melanoma. Aldesleukin and denileukin diftitox may stimulate the white blood cells to kill melanoma cells.
- Conditions
- Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
- Trial name
- NCT00945269
- Testing
- therapeutic autologous lymphocytes, aldesleukin, denileukin diftitox
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
This pilot trial studies the side effects of giving pembrolizumab together with stereotactic radiosurgery to treat patients with melanoma or non-small cell lung cancer that has spread to the brain.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Mucosal Melanoma, Ocular Melanoma
- Trial name
- NCT02858869
- Testing
- Pembrolizumab, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Emory University
Melanoma
IL2 Imaging in Metastatic Melanoma
T cell infiltration of tumor lesions is a known prognostic factor in several tumor types and is used as treatment mechanism in some of these tumor types.
- Trial name
- NCT02922283
- Testing
- IL2-PET scan, Tumor biopsy, CT scan
- Where
- Netherlands
- Volunteers
- 19 people
- Sponsor
- University Medical Center Groningen
Metastatic Melanoma, Head Neck Cancer
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This is a phase 1b/2, open-label, multicenter trial designed to evaluate the safety, tolerability, biologic activity, and preliminary efficacy of intratumoral SD-101 injections in combination with intravenous pembrolizumab in…
- Trial name
- NCT02521870
- Testing
- SD-101(1), Pembrolizumab, SD-101(2)
- Where
- 47 sites in United States, Australia and 2 more
- Volunteers
- 241 people
- Sponsor
- Dynavax Technologies Corporation
Melanoma (Skin)
Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
RATIONALE: Studying samples of blood, tumor tissue, and skin in the laboratory from patients with melanoma receiving hydroxychloroquine may help doctors understand the effect of hydroxychloroquine on biomarkers.
- Trial name
- NCT00962845
- Testing
- hydroxychloroquine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rutgers, The State University of New Jersey
Melanoma (Skin)
Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral…
- Trial name
- NCT00037037
- Testing
- MAGE-10.A2, MART-1 antigen, NY-ESO-1 peptide vaccine
- Where
- United States
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
This randomized phase III trial studies how well pembrolizumab works compared with the current standard of care, physician/patient choice of either high-dose recombinant interferon alfa-2B or ipilimumab, in treating patients with…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma
- Trial name
- NCT02506153
- Testing
- Biospecimen Collection, Computed Tomography, Ipilimumab
- Where
- 576 sites in United States, Canada and 1 more
- Volunteers
- 1,301 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.
The purpose of this study is compare the response rates in patients with metastatic melanoma treated with high-dose IL-2 to patients treated with high-dose IL-2 along with radiation therapy.
- Trial name
- SBRT/IL-2 (NCT01416831)
- Testing
- Radiation therapy and high-dose IL-2, High-dose IL-2
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Providence Health & Services
Stage IV Melanoma
A Study of Volociximab in Metastatic Melanoma
This is a Phase 2, multicenter, research study determining the effects of an investigational drug called volociximab in metastatic melanoma. The purpose of the study is to compare the clinical benefit and safety of volociximab.
- Trial name
- NCT00369395
- Testing
- volociximab
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- Abbott
Melanoma (Skin)
Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
- Trial name
- NCT00003027
- Testing
- aldesleukin, filgrastim, recombinant interferon alfa
- Where
- 94 sites in United States
- Volunteers
- 482 people
- Sponsor
- Eastern Cooperative Oncology Group
Metastatic Melanoma
A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma
This is an open-label, multicenter, Phase Ib study to evaluate the safety and therapeutic activity of RO6874281 in combination with pembrolizumab. The study will consist of 3 parts: a safety run-in (Part I: Cohorts 1.1.
- Trial name
- NCT03875079
- Testing
- RO6874281, Pembrolizumab
- Where
- 23 sites in United States, Australia and 5 more
- Volunteers
- 83 people
- Sponsor
- Hoffmann-La Roche
Unresectable Metastatic Melanoma
Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System
The goal of this prospective, low-interventional study is to develop and optimize a highly sensitive and specific method for the detection of the BRAF V600E mutation in liquid biopsy samples from patients with unresectable…
- Trial name
- BRAF SENS (NCT07870265)
- Testing
- Novel CRISPR/Cas12a Electrochemical Bioassay, Reference Standard Molecular Diagnostics (NGS and ddPCR), Serial Peripheral Blood Sampling for Liquid Biopsy
- Where
- Czechia
- Volunteers
- 17 people
- Sponsor
- Masaryk Memorial Cancer Institute
Brain and Central Nervous System Tumors, Intraocular Melanoma
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00003022
- Testing
- iodine I 131 monoclonal antibody 3F8
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
This study is being done to find the best dose of an investigational drug called NBM-BMX for people with metastatic uveal melanoma, a type of eye cancer that has spread to other parts of the body.
- Conditions
- Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic, Uveal Melanoma, Recurrent, Eye Cancer, Intraocular Melanoma
- Trial name
- NBM-BMX-UM (NCT07136181)
- Testing
- NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Novelwise Pharmaceutical Corporation
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
This phase II clinical trial studies how well thermal ablation and spine stereotactic radiosurgery work in treating patients with cancer that has spread to the spine (spine metastases) and is at risk for compressing the spinal…
- Conditions
- Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine
- Trial name
- NCT02713269
- Testing
- Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Stage IV Melanoma
Investigating Participation Patterns Among Stage IV Melanoma Patients
Clinical trials, specifically focused on stage IV melanoma, are crucial in assessing the safety and efficacy of new treatments for this disease.
- Trial name
- NCT06093594
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.